Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander hoofdstuk

2021 | OriginalPaper | Hoofdstuk

19. Psychofarmaca en de behandeling van slaapstoornissen

Auteurs : drs. Maaike van Veen, dr. Jeanine Kamphuis, dr. Rixt Riemersma-van der Lek

Gepubliceerd in: Slaapstoornissen in de psychiatrie

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Niet-medicamenteuze interventies zijn bij slaapstoornissen van groot belang en vaak de primaire behandelstap. Toch wordt om diverse redenen frequent gekozen voor inzet van medicatie; bijvoorbeeld door onvoldoende effect van de gekozen interventies of de noodzaak zo snel mogelijk slaapverbetering te induceren. Dan is kennis over de werking van en evidentie voor het gebruiken van diverse middelen voor het verbeteren van slaap noodzakelijk. Geregistreerde slaapmiddelen, zoals benzodiazepinen, zijn effectief op de korte termijn, maar kennen aanzienlijke nadelen. Off-labelgebruik van diverse psychofarmaca, met als doel slaapverbetering, is voor een aantal middelen goed verdedigbaar gezien de effecten op de slaaparchitectuur, maar ook deze hebben alle hun eigen (bijwerkingen)profiel. De invloed op de rijvaardigheid moet standaard besproken worden. Indien langdurig gebruikte slaapmiddelen afgebouwd moeten worden, zijn belangrijke uitgangspunten dit langzaam te doen en intensief te begeleiden. De voorschrijver van psychiatrische medicatie dient zich verder bewust te zijn van slaapverstorende bijwerkingen van diverse psychofarmaca.
Literatuur
go back to reference Anderson, S. L., & Vande Griend, J. P. (2014). Quetiapine for insomnia: A review of the literature. American Journal of Health System Pharmacy, 71(5), 394–402. Anderson, S. L., & Vande Griend, J. P. (2014). Quetiapine for insomnia: A review of the literature. American Journal of Health System Pharmacy, 71(5), 394–402.
go back to reference Aringhieri, S., Kolachalam, S., Gerace, C., et al. (2017). Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT2A receptor agonism. European Neuropsychopharmacology, 27(4), 383–398. PubMedCrossRef Aringhieri, S., Kolachalam, S., Gerace, C., et al. (2017). Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT2A receptor agonism. European Neuropsychopharmacology, 27(4), 383–398. PubMedCrossRef
go back to reference Atkin, T., Comai, S., & Gobbi, G. (2018). Drugs for insomnia beyond benzodiazepines: Pharmacology, clinical applications, and discovery. Pharmacological Reviews, 70(2), 197–245. PubMedCrossRef Atkin, T., Comai, S., & Gobbi, G. (2018). Drugs for insomnia beyond benzodiazepines: Pharmacology, clinical applications, and discovery. Pharmacological Reviews, 70(2), 197–245. PubMedCrossRef
go back to reference Ayabe, N., Okajima, I., Nakajima, S., et al. (2018). Effectiveness of cognitive behavioral therapy for pharmacotherapy-resistant chronic insomnia: A multi-center randomized controlled trial in Japan. Sleep Medicine, 50, 105–112. PubMedCrossRef Ayabe, N., Okajima, I., Nakajima, S., et al. (2018). Effectiveness of cognitive behavioral therapy for pharmacotherapy-resistant chronic insomnia: A multi-center randomized controlled trial in Japan. Sleep Medicine, 50, 105–112. PubMedCrossRef
go back to reference Baandrup, L, Ebdrup, B. H., Rasmussen, J. O., Lindschou, J., Gluud, C., & Glenthoj, B. Y. (2018). Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. The Cochrane Database of Systematic Reviews, 3, CD011481. Baandrup, L, Ebdrup, B. H., Rasmussen, J. O., Lindschou, J., Gluud, C., & Glenthoj, B. Y. (2018). Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. The Cochrane Database of Systematic Reviews, 3, CD011481.
go back to reference Ballester, P., Martinez, M. J., Inda, Md. M., et al. (2019). Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disability. Journal of Psychopharmacology, 33(11), 1395–1406. Ballester, P., Martinez, M. J., Inda, Md. M., et al. (2019). Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disability. Journal of Psychopharmacology, 33(11), 1395–1406.
go back to reference Barret, J. R., Tracy, D. K., & Giaroli, G. (2013). To sleep or not to sleep: A systematic review of the literature of pharmacological treatments of insomnia in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 23(10), 640–647. CrossRef Barret, J. R., Tracy, D. K., & Giaroli, G. (2013). To sleep or not to sleep: A systematic review of the literature of pharmacological treatments of insomnia in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 23(10), 640–647. CrossRef
go back to reference Bastien, C. H., LeBlanc, M., Carrier, J., & Morin, C. M. (2003). Sleep EEG power spectra, insomnia, and chronic use of benzodiazepines. Sleep, 26(3), 313–317. PubMedCrossRef Bastien, C. H., LeBlanc, M., Carrier, J., & Morin, C. M. (2003). Sleep EEG power spectra, insomnia, and chronic use of benzodiazepines. Sleep, 26(3), 313–317. PubMedCrossRef
go back to reference Bayard, M., Bailey, B., Acharya, D., Ambreen, F., Duggal, S., Kaur, T., et al. (2011). Bupropion and restless legs syndrome: a randomized controlled trial. Journal of the American Board of Family Medicine, 24(4), 422–428. PubMedCrossRef Bayard, M., Bailey, B., Acharya, D., Ambreen, F., Duggal, S., Kaur, T., et al. (2011). Bupropion and restless legs syndrome: a randomized controlled trial. Journal of the American Board of Family Medicine, 24(4), 422–428. PubMedCrossRef
go back to reference Beaulieu-Bonneau, S., Ivers, H., Guay, B., Morin, C. M. (2017). Long-term maintenance of therapeutic gains associated with cognitive-behavioral therapy for insomnia delivered alone or combined with zolpidem. Sleep, 1, 40(3). Beaulieu-Bonneau, S., Ivers, H., Guay, B., Morin, C. M. (2017). Long-term maintenance of therapeutic gains associated with cognitive-behavioral therapy for insomnia delivered alone or combined with zolpidem. Sleep, 1, 40(3).
go back to reference Berlant, J., & Van Kammen, D. P. (2002). Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: A preliminary report. Journal of Clinical Psychiatry, 63, 15–20. PubMedCrossRef Berlant, J., & Van Kammen, D. P. (2002). Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: A preliminary report. Journal of Clinical Psychiatry, 63, 15–20. PubMedCrossRef
go back to reference Biard, K., Douglass, A. B., & De Koninck, J. (2015). The effects of galantamine and buspirone on sleep structure: Implications for understanding sleep abnormalities in major depression. Journal of Psychopharmacology, 29(10), 1106–1111. PubMedCrossRef Biard, K., Douglass, A. B., & De Koninck, J. (2015). The effects of galantamine and buspirone on sleep structure: Implications for understanding sleep abnormalities in major depression. Journal of Psychopharmacology, 29(10), 1106–1111. PubMedCrossRef
go back to reference Brecht, S., Kajdasz, D., Ball, S., & Thase, M. E. (2008). Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder. International Clinical Psychopharmacology, 23, 317–324. PubMedCrossRef Brecht, S., Kajdasz, D., Ball, S., & Thase, M. E. (2008). Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder. International Clinical Psychopharmacology, 23, 317–324. PubMedCrossRef
go back to reference Brower, K. J., Myra Kim, H., Strobbe, S., Karam-Hage, M. A., Consens, F., & Zucker, R. A. (2008). A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcoholism, Clinical and Experimental Research, 32(8), 1429–1438. PubMedPubMedCentralCrossRef Brower, K. J., Myra Kim, H., Strobbe, S., Karam-Hage, M. A., Consens, F., & Zucker, R. A. (2008). A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcoholism, Clinical and Experimental Research, 32(8), 1429–1438. PubMedPubMedCentralCrossRef
go back to reference Brown, R. E., Basheer, R., McKenna, J. T., Strecker, R. E., & McCarley, R. W. (2012). Control of sleep and wakefulness. Physiological Reviews, 92(3), 1087–1187. PubMedCrossRef Brown, R. E., Basheer, R., McKenna, J. T., Strecker, R. E., & McCarley, R. W. (2012). Control of sleep and wakefulness. Physiological Reviews, 92(3), 1087–1187. PubMedCrossRef
go back to reference Carley, D. W., Olapade, C., Ruigt, G. S., & Radulovacki, M. (2007). Efficacy of mirtazapine in obstructive sleep apnea. Sleep, 30(1), 35–41. PubMedCrossRef Carley, D. W., Olapade, C., Ruigt, G. S., & Radulovacki, M. (2007). Efficacy of mirtazapine in obstructive sleep apnea. Sleep, 30(1), 35–41. PubMedCrossRef
go back to reference Carvalho, L., Gorenstein, C., Moreno, R., Pariante, C., & Markus, R. (2009). Effect of antidepressants on melatonin metabolite in depressed patients. Journal of Psychopharmacology, 23(3), 315–321. PubMedCrossRef Carvalho, L., Gorenstein, C., Moreno, R., Pariante, C., & Markus, R. (2009). Effect of antidepressants on melatonin metabolite in depressed patients. Journal of Psychopharmacology, 23(3), 315–321. PubMedCrossRef
go back to reference Cohrs, S. (2008). Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs, 22(11), 939–962. PubMedCrossRef Cohrs, S. (2008). Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs, 22(11), 939–962. PubMedCrossRef
go back to reference Cohrs, S., Rodenbeck, A., Guan, Z., Pohlmann, K., Jordan, W., Meier, A., et al. (2004). Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl), 174(3), 421–429. Cohrs, S., Rodenbeck, A., Guan, Z., Pohlmann, K., Jordan, W., Meier, A., et al. (2004). Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl), 174(3), 421–429.
go back to reference Coogan, A. N., Schenk, M., Palm, D., Uzoni, A., Grube, J., Tsang, A. H., et al. (2019). Impact of adult attention deficit hyperactivity disorder and medication status on sleep/wake behavior and molecular circadian rhythms. Neuropsychopharmacology, 44(7), 1198–1206. PubMedPubMedCentralCrossRef Coogan, A. N., Schenk, M., Palm, D., Uzoni, A., Grube, J., Tsang, A. H., et al. (2019). Impact of adult attention deficit hyperactivity disorder and medication status on sleep/wake behavior and molecular circadian rhythms. Neuropsychopharmacology, 44(7), 1198–1206. PubMedPubMedCentralCrossRef
go back to reference Cosci, F., & Chouinard, G. (2020). Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychotherapy and Psychosomatics, 7, 1–24. CrossRef Cosci, F., & Chouinard, G. (2020). Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychotherapy and Psychosomatics, 7, 1–24. CrossRef
go back to reference Crochet, S., & Sakai, K. (1999). Alpha-2 adrenoceptor mediated paradoxical (REM) sleep inhibition in the cat. NeuroReport, 10(10), 2199–2204. PubMedCrossRef Crochet, S., & Sakai, K. (1999). Alpha-2 adrenoceptor mediated paradoxical (REM) sleep inhibition in the cat. NeuroReport, 10(10), 2199–2204. PubMedCrossRef
go back to reference Dallaspezia, S., & Benedetti, F. (2015). Chronobiology of bipolar disorder: Therapeutic implication. Current Psychiatry Reports, 17, 68. CrossRef Dallaspezia, S., & Benedetti, F. (2015). Chronobiology of bipolar disorder: Therapeutic implication. Current Psychiatry Reports, 17, 68. CrossRef
go back to reference Darker, C. D., Sweeney, B. P., Barry, J. M., Farrell, M. F., & Donnelly-Swift, E. (2015). Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. The Cochrane Database of Systematic Reviews, (5), CD009652. Darker, C. D., Sweeney, B. P., Barry, J. M., Farrell, M. F., & Donnelly-Swift, E. (2015). Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. The Cochrane Database of Systematic Reviews, (5), CD009652.
go back to reference Dassanayake, T., Michie, P., Carter, G., & Jones, A. (2011). Effects of benzodiazepines, antidepressants and opioids on driving: A systematic review and meta-analysis of epidemiological and experimental evidence. Drug Safety, 34(2), 125–156. Dassanayake, T., Michie, P., Carter, G., & Jones, A. (2011). Effects of benzodiazepines, antidepressants and opioids on driving: A systematic review and meta-analysis of epidemiological and experimental evidence. Drug Safety, 34(2), 125–156.
go back to reference De Smidt, P. C., & Spaans, H. P. (2011). Serotoninesyndroom bij tranylcypromine en lage dosis trazodon; 5-ht2a, 5-ht1a, sert en selectiviteit. Psyfar, 3, 50–53. De Smidt, P. C., & Spaans, H. P. (2011). Serotoninesyndroom bij tranylcypromine en lage dosis trazodon; 5-ht2a, 5-ht1a, sert en selectiviteit. Psyfar, 3, 50–53.
go back to reference Doghramji, K., & Jangro, W. C. (2016). Adverse effects of psychotropic medications on sleep. Sleep Medicine Clinics, 11(4), 503–514. PubMedCrossRef Doghramji, K., & Jangro, W. C. (2016). Adverse effects of psychotropic medications on sleep. Sleep Medicine Clinics, 11(4), 503–514. PubMedCrossRef
go back to reference Englisch, S., Jung, H. S., Lewien, A., et al. (2016). Agomelatine for the treatment of major depressive episodes in schizophrenia-spectrum disorders: An open-prospective proof-of-concept study. Journal of Clinical Psychopharmacology, 36, 597–607. PubMed Englisch, S., Jung, H. S., Lewien, A., et al. (2016). Agomelatine for the treatment of major depressive episodes in schizophrenia-spectrum disorders: An open-prospective proof-of-concept study. Journal of Clinical Psychopharmacology, 36, 597–607. PubMed
go back to reference Everitt, H., Baldwin, D. S., Stuart, B., Lipinska, G., Mayers, A., Malizia, A. L., et al. (2018). Antidepressants for insomnia in adults. Cochrane Database of Systematic Reviews, 5. Art. No.: CD010753. Everitt, H., Baldwin, D. S., Stuart, B., Lipinska, G., Mayers, A., Malizia, A. L., et al. (2018). Antidepressants for insomnia in adults. Cochrane Database of Systematic Reviews, 5. Art. No.: CD010753.
go back to reference Faraone, S. V. (2018). The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neuroscience and Biobehavioral Reviews, 87, 255–270. PubMedCrossRefPubMedCentral Faraone, S. V. (2018). The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neuroscience and Biobehavioral Reviews, 87, 255–270. PubMedCrossRefPubMedCentral
go back to reference Fluyau, D., Revadigar, N., & Manobianco, B. E. (2018). Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Therapeutic Advances in Psychopharmacology, 8(5), 147–168. PubMedPubMedCentralCrossRef Fluyau, D., Revadigar, N., & Manobianco, B. E. (2018). Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Therapeutic Advances in Psychopharmacology, 8(5), 147–168. PubMedPubMedCentralCrossRef
go back to reference Fung, C. H., Martin, J. L., Alessi, C., Dzierzewski, J. M., Cook, I. A., Moore, A., et al. (2019). Hypnotic discontinuation using a blinded (masked) tapering approach: A case series. Front Psychiatry, 24(10), 717. Fung, C. H., Martin, J. L., Alessi, C., Dzierzewski, J. M., Cook, I. A., Moore, A., et al. (2019). Hypnotic discontinuation using a blinded (masked) tapering approach: A case series. Front Psychiatry, 24(10), 717.
go back to reference Geoffroy, P. A., Samalin, L., Llorca, P. M., Curis, E., & Bellivier, F. (2016). Influence of lithium on sleep and chronotypes in remitted patients with bipolar disorder. Journal of Affective Disorders, 204, 32–39. PubMedCrossRef Geoffroy, P. A., Samalin, L., Llorca, P. M., Curis, E., & Bellivier, F. (2016). Influence of lithium on sleep and chronotypes in remitted patients with bipolar disorder. Journal of Affective Disorders, 204, 32–39. PubMedCrossRef
go back to reference Glass, J., Lanctôt, K. L., Herrmann, N., Sproule, B. A., & Busto, U. E. (2005 Nov 19). Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits. BMJ, 331(7526), 1169. Glass, J., Lanctôt, K. L., Herrmann, N., Sproule, B. A., & Busto, U. E. (2005 Nov 19). Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits. BMJ, 331(7526), 1169.
go back to reference González, S., Moreno-Delgado, D., Moreno, E., Pérez-Capote, K., Franco, R., Mallol, J., et al. (2012). Circadian-related heteromerization of adrenergic and dopamine D 4 receptors modulates melatonin synthesis and release in the pineal gland. PLoS Biology, 10(6), e1001347. PubMedPubMedCentralCrossRef González, S., Moreno-Delgado, D., Moreno, E., Pérez-Capote, K., Franco, R., Mallol, J., et al. (2012). Circadian-related heteromerization of adrenergic and dopamine D 4 receptors modulates melatonin synthesis and release in the pineal gland. PLoS Biology, 10(6), e1001347. PubMedPubMedCentralCrossRef
go back to reference Gould, R. L., Coulson, M. C., Patel, N., Highton-Williamson, E., & Howard, R. J. (2015). Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. British Journal of Psychiatry, 204(2), 98–107. CrossRef Gould, R. L., Coulson, M. C., Patel, N., Highton-Williamson, E., & Howard, R. J. (2015). Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. British Journal of Psychiatry, 204(2), 98–107. CrossRef
go back to reference Hale, A., Corral, R.-M., Mencacci, C., et al. (2010). Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. International Clinical Psychopharmacology, 25, 305–314. PubMedCrossRef Hale, A., Corral, R.-M., Mencacci, C., et al. (2010). Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. International Clinical Psychopharmacology, 25, 305–314. PubMedCrossRef
go back to reference Hassinger, A. B., Bletnisky, N., Dudekula, R., & El-Solh, A. A. (2020). Selecting a pharmacotherapy regimen for patients with chronic insomnia. Expert Opinion on Pharmacotherapy, 23, 1–9. Hassinger, A. B., Bletnisky, N., Dudekula, R., & El-Solh, A. A. (2020). Selecting a pharmacotherapy regimen for patients with chronic insomnia. Expert Opinion on Pharmacotherapy, 23, 1–9.
go back to reference Hohagen, F., Rink, K., Käppler, C., Schramm, E., Riemann, D., Weyerer, S., et al. (1993). Prevalence and treatment of insomnia in general practice. A longitudinal study. European Archives of Psychiatry and Clinical Neuroscience, 242(6), 329–336. Hohagen, F., Rink, K., Käppler, C., Schramm, E., Riemann, D., Weyerer, S., et al. (1993). Prevalence and treatment of insomnia in general practice. A longitudinal study. European Archives of Psychiatry and Clinical Neuroscience, 242(6), 329–336.
go back to reference Holsboer-Trachsler, E., & Prieto, R. (2013). Effects of pregabalin on sleep in generalized anxiety disorder. International Journal of Neuropsychopharmacology, 16(4), 925–936. CrossRefPubMed Holsboer-Trachsler, E., & Prieto, R. (2013). Effects of pregabalin on sleep in generalized anxiety disorder. International Journal of Neuropsychopharmacology, 16(4), 925–936. CrossRefPubMed
go back to reference Huynh, N., Lavigne, G. J., Lanfranchi, P. A., Montplaisir, J. Y., & De Champlain, J. (2006). The effect of 2 sympatholytic medications–propranolol and clonidine–on sleep bruxism: Experimental randomized controlled studies. Sleep, 29, 307–316. PubMedCrossRef Huynh, N., Lavigne, G. J., Lanfranchi, P. A., Montplaisir, J. Y., & De Champlain, J. (2006). The effect of 2 sympatholytic medications–propranolol and clonidine–on sleep bruxism: Experimental randomized controlled studies. Sleep, 29, 307–316. PubMedCrossRef
go back to reference Jaffer, K. Y., Chang, T., Vanle, B., Dang, J., Steiner, A. J., Loera, N., et al. (2017). Trazodone for insomnia: A systematic review. Innovations in Clinical Neuroscience, 14(7–8), 24–34. PubMedPubMedCentral Jaffer, K. Y., Chang, T., Vanle, B., Dang, J., Steiner, A. J., Loera, N., et al. (2017). Trazodone for insomnia: A systematic review. Innovations in Clinical Neuroscience, 14(7–8), 24–34. PubMedPubMedCentral
go back to reference Jain, S. V., & Glauser, T. A. (2014). Effects of epilepsy treatments on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics. Epilepsia, 55(1), 26–37. CrossRefPubMed Jain, S. V., & Glauser, T. A. (2014). Effects of epilepsy treatments on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics. Epilepsia, 55(1), 26–37. CrossRefPubMed
go back to reference Kamphuis, J., Taxis, K., Schuiling-Veninga, C. C. M., Bruggeman, R., & Lancel, M. (2015). Off-label prescriptions of low-dose quetiapine and mirtazapine for insomnia in The Netherlands. Journal of Clinical Psychopharmacology, 35, 468–470. PubMed Kamphuis, J., Taxis, K., Schuiling-Veninga, C. C. M., Bruggeman, R., & Lancel, M. (2015). Off-label prescriptions of low-dose quetiapine and mirtazapine for insomnia in The Netherlands. Journal of Clinical Psychopharmacology, 35, 468–470. PubMed
go back to reference Karsten, J., Hagenauw, L. A., Kamphuis, J., & Lancel, M. (2017). Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial. Journal of Psychopharmacology, 31(3), 327–337. PubMedCrossRef Karsten, J., Hagenauw, L. A., Kamphuis, J., & Lancel, M. (2017). Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial. Journal of Psychopharmacology, 31(3), 327–337. PubMedCrossRef
go back to reference Khachatryan, D., Groll, D., Booij, L., Sepehry, A. A., & Schütz, C. G. (2016). Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: A systematic review and meta-analysis of randomized controlled trials. General Hospital Psychiatry, 39, 46–52. PubMedCrossRef Khachatryan, D., Groll, D., Booij, L., Sepehry, A. A., & Schütz, C. G. (2016). Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: A systematic review and meta-analysis of randomized controlled trials. General Hospital Psychiatry, 39, 46–52. PubMedCrossRef
go back to reference Kim, S. W., Shin, I. S., Kim, J. M., Park, K. H., Youn, T., & Yoon, J. S. (2008). Factors potentiating the risk of mirtazapine-associated restless legs syndrome. Human Psychopharmacology, 23(7), 615–620. PubMedCrossRef Kim, S. W., Shin, I. S., Kim, J. M., Park, K. H., Youn, T., & Yoon, J. S. (2008). Factors potentiating the risk of mirtazapine-associated restless legs syndrome. Human Psychopharmacology, 23(7), 615–620. PubMedCrossRef
go back to reference Kim, S. W., Shin, I. S., Kim, J. M., Yang, S. J., Shin, H. Y., & Yoon, J. S. (2005). Bupropion may improve restless legs syndrome: A report of three cases. Clinical Neuropharmacology, 28(6), 298–301. PubMedCrossRef Kim, S. W., Shin, I. S., Kim, J. M., Yang, S. J., Shin, H. Y., & Yoon, J. S. (2005). Bupropion may improve restless legs syndrome: A report of three cases. Clinical Neuropharmacology, 28(6), 298–301. PubMedCrossRef
go back to reference Kluge, M., Schüssler, P., & Steiger, A. (2007). Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. European Neuropsychopharmacology, 17, 527–531. PubMedCrossRef Kluge, M., Schüssler, P., & Steiger, A. (2007). Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. European Neuropsychopharmacology, 17, 527–531. PubMedCrossRef
go back to reference Kolla, B. P., Mansukhani, M. P., & Bostwick, J. M. (2018). The influence of antidepressants on restless legs syndrome and periodic limb movements: A systematic review. Sleep Medicine Reviews, 38, 131–140. PubMedCrossRef Kolla, B. P., Mansukhani, M. P., & Bostwick, J. M. (2018). The influence of antidepressants on restless legs syndrome and periodic limb movements: A systematic review. Sleep Medicine Reviews, 38, 131–140. PubMedCrossRef
go back to reference Kooy, A., Peters-Romeyn, B. M. T., & Van Gool, A. R. (1993). Mono-amino-oxydase-remmers: intoxicaties en interacties. Nederlands Tijdschrift voor Geneeskunde, 137(38), 1910–1914. PubMed Kooy, A., Peters-Romeyn, B. M. T., & Van Gool, A. R. (1993). Mono-amino-oxydase-remmers: intoxicaties en interacties. Nederlands Tijdschrift voor Geneeskunde, 137(38), 1910–1914. PubMed
go back to reference Kripke, D. F. (2015). Is suvorexant a better choice than alternative hypnotics? F1000Research, 4, 456. Kripke, D. F. (2015). Is suvorexant a better choice than alternative hypnotics? F1000Research, 4, 456.
go back to reference Krystal, A. D. (2015). New developments in insomnia medications of relevance to mental health disorders. Psychiatric Clinics of North America, 38(4), 843–860. PubMedCrossRef Krystal, A. D. (2015). New developments in insomnia medications of relevance to mental health disorders. Psychiatric Clinics of North America, 38(4), 843–860. PubMedCrossRef
go back to reference Lähteenmäki, R., Puustinen, J., Vahlberg, T., Lyles, A., Neuvonen, P. J., Partinen, M., et al. (2014). Melatonin for sedative withdrawal in older patients with primary insomnia: A randomized double-blind placebo-controlled trial. British Journal of Clinical Pharmacology, 77(6), 975–985. PubMedCrossRef Lähteenmäki, R., Puustinen, J., Vahlberg, T., Lyles, A., Neuvonen, P. J., Partinen, M., et al. (2014). Melatonin for sedative withdrawal in older patients with primary insomnia: A randomized double-blind placebo-controlled trial. British Journal of Clinical Pharmacology, 77(6), 975–985. PubMedCrossRef
go back to reference Lancel, M., & Karsten, J. (2013). Antidepressiva: Effecten op de slaap. Psyfar, 3, 20–26. Lancel, M., & Karsten, J. (2013). Antidepressiva: Effecten op de slaap. Psyfar, 3, 20–26.
go back to reference Lemoine, P., Guilleminault, C., & Alvarez, E. (2007). Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. Journal of Clinical Psychiatry, 68, 1723–1732. PubMedCrossRef Lemoine, P., Guilleminault, C., & Alvarez, E. (2007). Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. Journal of Clinical Psychiatry, 68, 1723–1732. PubMedCrossRef
go back to reference Liguori, C., Ferini-Strambi, L., Izzi, F., et al. (2019). Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: A retrospective questionnaire analysis. British Journal of Clinical Pharmacology, 85(1), 240–244. PubMedCrossRef Liguori, C., Ferini-Strambi, L., Izzi, F., et al. (2019). Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: A retrospective questionnaire analysis. British Journal of Clinical Pharmacology, 85(1), 240–244. PubMedCrossRef
go back to reference Linden, M., & Thiels, C. (2001). Epidemiology of prescriptions for neuroleptic drugs: Tranquilizers rather than antipsychotics. Pharmacopsychiatry., 34(4), 150–154. PubMedCrossRef Linden, M., & Thiels, C. (2001). Epidemiology of prescriptions for neuroleptic drugs: Tranquilizers rather than antipsychotics. Pharmacopsychiatry., 34(4), 150–154. PubMedCrossRef
go back to reference Lo, H. S., Yang, C. M., Lo, H. G., Lee, C. Y., Ting, H., & Tzang, B. S. (2010). Treatment effects of gabapentin for primary insomnia. Clinical Neuropharmacology, 33(2), 84–90. PubMedCrossRef Lo, H. S., Yang, C. M., Lo, H. G., Lee, C. Y., Ting, H., & Tzang, B. S. (2010). Treatment effects of gabapentin for primary insomnia. Clinical Neuropharmacology, 33(2), 84–90. PubMedCrossRef
go back to reference Manconi, M., Ferri, R., Miano, S., Maestri, M., Bottasini, V., Zucconi, M., et al. (2017). Sleep architecture in insomniacs with severe benzodiazepine abuse. Clinical Neurophysiology, 128(6), 875–881. PubMedCrossRef Manconi, M., Ferri, R., Miano, S., Maestri, M., Bottasini, V., Zucconi, M., et al. (2017). Sleep architecture in insomniacs with severe benzodiazepine abuse. Clinical Neurophysiology, 128(6), 875–881. PubMedCrossRef
go back to reference Marshall, N. S., Brendon, Y. J., Desai, A. V., et al. (2008). Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea. Sleep, 31, 824–831. PubMedPubMedCentralCrossRef Marshall, N. S., Brendon, Y. J., Desai, A. V., et al. (2008). Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea. Sleep, 31, 824–831. PubMedPubMedCentralCrossRef
go back to reference Mason, M., Cates, C. J., & Smith, I. (2015). Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database of Systematic Reviews, 14(7), CD011090. Mason, M., Cates, C. J., & Smith, I. (2015). Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database of Systematic Reviews, 14(7), CD011090.
go back to reference Mattila, T., Stoyanova, V., Elferink, A., Gispen-de Wied, C., De Boer, A., & Wohlfarth, T. (2011). Insomnia medication: do published studies reflect the complete picture of efficacy and safety? European Neuropsychopharmacology, 21(7), 500–507. PubMedCrossRef Mattila, T., Stoyanova, V., Elferink, A., Gispen-de Wied, C., De Boer, A., & Wohlfarth, T. (2011). Insomnia medication: do published studies reflect the complete picture of efficacy and safety? European Neuropsychopharmacology, 21(7), 500–507. PubMedCrossRef
go back to reference Mayers, A. G., & Baldwin, D. S. (2005). Antidepressants and their effect on sleep. Human Psychopharmacology Clinical and Experimental, 20, 533–559. PubMedCrossRef Mayers, A. G., & Baldwin, D. S. (2005). Antidepressants and their effect on sleep. Human Psychopharmacology Clinical and Experimental, 20, 533–559. PubMedCrossRef
go back to reference Mazza, M., Losurdo, A., Testani, E., et al. (2014). Polysomnographic findings in a cohort of chronic insomnia patients with benzodiazepine abuse. Journal of Clinical Sleep Medicine, 10(1), 35–42. PubMedPubMedCentralCrossRef Mazza, M., Losurdo, A., Testani, E., et al. (2014). Polysomnographic findings in a cohort of chronic insomnia patients with benzodiazepine abuse. Journal of Clinical Sleep Medicine, 10(1), 35–42. PubMedPubMedCentralCrossRef
go back to reference McGlashan, E. M., Nandam, L. S., Vidafar, P., et al. (2018). The SSRI citalopram increases the sensitivity of the human circadian system to light in an acute dose. Psychopharmacology (Berl), 235, 3201–3209. CrossRef McGlashan, E. M., Nandam, L. S., Vidafar, P., et al. (2018). The SSRI citalopram increases the sensitivity of the human circadian system to light in an acute dose. Psychopharmacology (Berl), 235, 3201–3209. CrossRef
go back to reference Menon, V., & Madhavapuri, P. (2017). Low-dose mirtazapine-induced nightmares necessitating its discontinuation in a young adult female. Journal of Pharmacology and Pharmacotherapeutics, 8, 182–184. PubMedCrossRefPubMedCentral Menon, V., & Madhavapuri, P. (2017). Low-dose mirtazapine-induced nightmares necessitating its discontinuation in a young adult female. Journal of Pharmacology and Pharmacotherapeutics, 8, 182–184. PubMedCrossRefPubMedCentral
go back to reference Mitchell, M. D., Gehrman, P., Perlis, M., & Umscheid, C. A. (2012). Comparative effectiveness of cognitive behavioral therapy for insomnia: A systematic review. BMC Family Practice, 25(13), 40. CrossRef Mitchell, M. D., Gehrman, P., Perlis, M., & Umscheid, C. A. (2012). Comparative effectiveness of cognitive behavioral therapy for insomnia: A systematic review. BMC Family Practice, 25(13), 40. CrossRef
go back to reference Miyazaki, S., Uchida, S., Mukai, J., & Nishihara, K. (2004). Clonidine effects on all-night human sleep: Opposite action of low- and medium-dose clonidine on human NREM–REM sleep proportion. Psychiatry and Clinical Neurosciences, 58(2), 138–144. PubMedCrossRef Miyazaki, S., Uchida, S., Mukai, J., & Nishihara, K. (2004). Clonidine effects on all-night human sleep: Opposite action of low- and medium-dose clonidine on human NREM–REM sleep proportion. Psychiatry and Clinical Neurosciences, 58(2), 138–144. PubMedCrossRef
go back to reference Molemans Praktische Psychofarmacologie, 2015 geheel herziene editie, onder redactie van P. Naarding en E. Beers. Molemans Praktische Psychofarmacologie, 2015 geheel herziene editie, onder redactie van P. Naarding en E. Beers.
go back to reference Monti, J. M., Alterwain, P., & Monti, D. (1990). The effects of moclobemide on nocturnal sleep of depressed patients. Journal of Affective Disorders, 20(3), 201–208. PubMedCrossRef Monti, J. M., Alterwain, P., & Monti, D. (1990). The effects of moclobemide on nocturnal sleep of depressed patients. Journal of Affective Disorders, 20(3), 201–208. PubMedCrossRef
go back to reference Monti, J. M., & Monti, D. (2000). Histamine H1 receptor antagonists in the treatment of insomnia. Molecular Diagnosis & Therapy, 13, 87–96. Monti, J. M., & Monti, D. (2000). Histamine H1 receptor antagonists in the treatment of insomnia. Molecular Diagnosis & Therapy, 13, 87–96.
go back to reference Monti, J. M., Torterolo, P., & Pandi Perumal, S. R. (2017). The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep Medicine Reviews, 33, 51–57. PubMedCrossRef Monti, J. M., Torterolo, P., & Pandi Perumal, S. R. (2017). The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep Medicine Reviews, 33, 51–57. PubMedCrossRef
go back to reference Morgenthaler, T. I., Auerbach, S., Casey, K. R., et al. (2018). Position paper for the treatment of nightmare disorder in adults: An American Academy of Sleep Medicine position paper. Journal of Clinical Sleep Medicine, 14(6), 1041–1055. PubMedPubMedCentralCrossRef Morgenthaler, T. I., Auerbach, S., Casey, K. R., et al. (2018). Position paper for the treatment of nightmare disorder in adults: An American Academy of Sleep Medicine position paper. Journal of Clinical Sleep Medicine, 14(6), 1041–1055. PubMedPubMedCentralCrossRef
go back to reference Morin, C. M., Vallières, A., Guay, B., Ivers, H., Savard, J., Mérette, C., et al. (2009). Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: A randomized controlled trial. JAMA, 301(19), 2005–2015. PubMedPubMedCentralCrossRef Morin, C. M., Vallières, A., Guay, B., Ivers, H., Savard, J., Mérette, C., et al. (2009). Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: A randomized controlled trial. JAMA, 301(19), 2005–2015. PubMedPubMedCentralCrossRef
go back to reference Morrissette, D. A., & Stahl, S. M. (2014). CME Review article; modulating the serotonin system in the treatment of major depressive disorder. CNS Spectrums, 1–15. Morrissette, D. A., & Stahl, S. M. (2014). CME Review article; modulating the serotonin system in the treatment of major depressive disorder. CNS Spectrums, 1–15.
go back to reference Nagay, A. (2016). Clonidine use in psychiatry: Panacea or panache? Pharmacology, 98, 87–92. CrossRef Nagay, A. (2016). Clonidine use in psychiatry: Panacea or panache? Pharmacology, 98, 87–92. CrossRef
go back to reference Nguyen, M., Tharani, S., Rahmani, M., & Shapiro, M. (2014). A review of the use of clonidine as a sleep aid in the child and adolescent population. Clinical Pediatrics, 53(3), 211–216. PubMedCrossRef Nguyen, M., Tharani, S., Rahmani, M., & Shapiro, M. (2014). A review of the use of clonidine as a sleep aid in the child and adolescent population. Clinical Pediatrics, 53(3), 211–216. PubMedCrossRef
go back to reference Nieuwhof, M. A. E. (2019). Off-labelgebruik mirtazapine als slaapmiddel. Geneesmiddelen Bulletin, 53, 66–68. Nieuwhof, M. A. E. (2019). Off-labelgebruik mirtazapine als slaapmiddel. Geneesmiddelen Bulletin, 53, 66–68.
go back to reference Nolen, W. A., Haffmans, P. M., Bouvy, P. F., & Duivenvoorden, H. J. (1993). Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. Journal of Affective Disorders, 28, 189–197. Nolen, W. A., Haffmans, P. M., Bouvy, P. F., & Duivenvoorden, H. J. (1993). Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. Journal of Affective Disorders, 28, 189–197.
go back to reference Odagaki, Y., Toyoshima, R., & Yamauchi, T. (2005). Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. Journal of Psychopharmacology, 19(3), 235–241. PubMedCrossRef Odagaki, Y., Toyoshima, R., & Yamauchi, T. (2005). Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. Journal of Psychopharmacology, 19(3), 235–241. PubMedCrossRef
go back to reference Ostadhadi, S., Khan, M. I., Norouzi-Javidan, A., Chamanar, M., Jazaeri, F., Zolfaghari, S., et al. (2016). Involvement of NMDA receptors and L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in the antidepressant-like effects of topiramate in mice forced swimming test. Brain Research Bulletin, 122, 62–70. PubMedCrossRef Ostadhadi, S., Khan, M. I., Norouzi-Javidan, A., Chamanar, M., Jazaeri, F., Zolfaghari, S., et al. (2016). Involvement of NMDA receptors and L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in the antidepressant-like effects of topiramate in mice forced swimming test. Brain Research Bulletin, 122, 62–70. PubMedCrossRef
go back to reference Ott, G. E., Rao, U., Lin, K. M., Gertsik, L., & Poland, R. E. (2004). Effect of treatment with bupropion on EEG sleep: Relationship to antidepressant response. International Journal of Neuropsychopharmacology, 7, 275–281. CrossRefPubMed Ott, G. E., Rao, U., Lin, K. M., Gertsik, L., & Poland, R. E. (2004). Effect of treatment with bupropion on EEG sleep: Relationship to antidepressant response. International Journal of Neuropsychopharmacology, 7, 275–281. CrossRefPubMed
go back to reference Palazidou, E., Papadopoulos, A., Sitsen, A., et al. (1989). An alpha2 adrenoceptor antagonist, Org 3770, enhances nocturnal melatonin secretion in man. Psychopharmacology (Berl), 97, 115–117. CrossRef Palazidou, E., Papadopoulos, A., Sitsen, A., et al. (1989). An alpha2 adrenoceptor antagonist, Org 3770, enhances nocturnal melatonin secretion in man. Psychopharmacology (Berl), 97, 115–117. CrossRef
go back to reference Page, R. L., Ruscin, J. M., Bainbridge, J. L., & Brieke, A. A. (2008). Restless legs syndrome induced by escitalopram: Case report and review of the literature. Pharmacotherapy, 28(2), 271–280. PubMedCrossRef Page, R. L., Ruscin, J. M., Bainbridge, J. L., & Brieke, A. A. (2008). Restless legs syndrome induced by escitalopram: Case report and review of the literature. Pharmacotherapy, 28(2), 271–280. PubMedCrossRef
go back to reference Parrino, L., & Terzano, M. G. (1996). Polysomnographic effects of hypnotic drugs. A review. Psychopharmacology (Berl), 126(1), 1–16. CrossRef Parrino, L., & Terzano, M. G. (1996). Polysomnographic effects of hypnotic drugs. A review. Psychopharmacology (Berl), 126(1), 1–16. CrossRef
go back to reference Parrino, L., Smerieri, A., Giglia, F., Milioli, G., De Paolis, F., & Terzano, M. G. (2008). Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia. Clinical Neuropharmacology, 31(1), 40–50. PubMedCrossRef Parrino, L., Smerieri, A., Giglia, F., Milioli, G., De Paolis, F., & Terzano, M. G. (2008). Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia. Clinical Neuropharmacology, 31(1), 40–50. PubMedCrossRef
go back to reference Patel, R., & Dickenson, A. H. (2016). Mechanisms of the gabapentinoids and α 2 δ-1 calcium channel subunit in neuropathic pain. Pharmacology Research and Perspectives, 4(2), e00205. PubMedCrossRefPubMedCentral Patel, R., & Dickenson, A. H. (2016). Mechanisms of the gabapentinoids and α 2 δ-1 calcium channel subunit in neuropathic pain. Pharmacology Research and Perspectives, 4(2), e00205. PubMedCrossRefPubMedCentral
go back to reference Peckham, A. M., Evoy, K. E., Ochs, L., & Covvey, J. R. (2018). Gabapentin for off-label use: Evidence-based or cause for concern? Subst Abuse, 12, 1178221818801311. PubMedPubMedCentral Peckham, A. M., Evoy, K. E., Ochs, L., & Covvey, J. R. (2018). Gabapentin for off-label use: Evidence-based or cause for concern? Subst Abuse, 12, 1178221818801311. PubMedPubMedCentral
go back to reference Pillai, V., Cheng, P., Kalmbach, D. A., Roehrs, T., Roth, T., & Drake, C. L. (2016). Prevalence and predictors of prescription sleep aid use among individuals with DSM-5 insomnia: The role of hyperarousal. Sleep, 39(4), 825–832. PubMedPubMedCentralCrossRef Pillai, V., Cheng, P., Kalmbach, D. A., Roehrs, T., Roth, T., & Drake, C. L. (2016). Prevalence and predictors of prescription sleep aid use among individuals with DSM-5 insomnia: The role of hyperarousal. Sleep, 39(4), 825–832. PubMedPubMedCentralCrossRef
go back to reference Pillai, V., Roth, T., Roehrs, T., Moss, K., Peterson, E. L., & Drake, C. L. (2017). Effectiveness of benzodiazepine receptor agonists in the treatment of insomnia: An examination of response and remission rates. Sleep, 40(2), zsw044. Pillai, V., Roth, T., Roehrs, T., Moss, K., Peterson, E. L., & Drake, C. L. (2017). Effectiveness of benzodiazepine receptor agonists in the treatment of insomnia: An examination of response and remission rates. Sleep, 40(2), zsw044.
go back to reference Poyares, D., Guilleminault, C., Ohayon, M. M., & Tufik, S. (2004). Chronic benzodiazepine usage and withdrawal in insomnia patients. Journal of Psychiatric Research, 38(3), 327–334. PubMedCrossRef Poyares, D., Guilleminault, C., Ohayon, M. M., & Tufik, S. (2004). Chronic benzodiazepine usage and withdrawal in insomnia patients. Journal of Psychiatric Research, 38(3), 327–334. PubMedCrossRef
go back to reference Puustinen, J., Lähteenmäki, R., Polo-Kantola, P., Salo, P., Vahlberg, T., Lyles, A., et al. (2014). Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. European Journal of Clinical Pharmacology, 70(3), 319–329. PubMedCrossRef Puustinen, J., Lähteenmäki, R., Polo-Kantola, P., Salo, P., Vahlberg, T., Lyles, A., et al. (2014). Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. European Journal of Clinical Pharmacology, 70(3), 319–329. PubMedCrossRef
go back to reference Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125–133. PubMedCrossRef Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125–133. PubMedCrossRef
go back to reference Quera-Salva, M.-A., Haja, G., Philip, P., et al. (2011). Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. International Clinical Psychopharmacology, 26, 252–262. PubMedCrossRef Quera-Salva, M.-A., Haja, G., Philip, P., et al. (2011). Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. International Clinical Psychopharmacology, 26, 252–262. PubMedCrossRef
go back to reference Rajan, R., & Syn, Y. M. (2017). Reevaluating antidepressant selection in patients with bruxism and temporomandibular joint disorder. Journal of Psychiatric Practice, 23, 173–179. PubMedCrossRef Rajan, R., & Syn, Y. M. (2017). Reevaluating antidepressant selection in patients with bruxism and temporomandibular joint disorder. Journal of Psychiatric Practice, 23, 173–179. PubMedCrossRef
go back to reference Raskind, M. A., Peskind, E. R., Chow, B., et al. (2018). Trial of prazosin for post-traumatic stress disorder in military veterans. The New England Journal of Medicine, 378(6), 507–517. PubMedCrossRef Raskind, M. A., Peskind, E. R., Chow, B., et al. (2018). Trial of prazosin for post-traumatic stress disorder in military veterans. The New England Journal of Medicine, 378(6), 507–517. PubMedCrossRef
go back to reference Richards, A., Inslicht, S., Ruoff, L. M., Metzler, T. J., Goldstein, L. A., Chapman, C. M., et al. (2018). An open-label study of doxazosin extended-release for PTSD: Findings and recommendations for future research on doxazosin. Focus (American Psychiatric Publishing), 16(1), 67–73. Richards, A., Inslicht, S., Ruoff, L. M., Metzler, T. J., Goldstein, L. A., Chapman, C. M., et al. (2018). An open-label study of doxazosin extended-release for PTSD: Findings and recommendations for future research on doxazosin. Focus (American Psychiatric Publishing), 16(1), 67–73.
go back to reference Riemann, D., Baglioni, C., & Bassetti, C. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675–700. PubMedCrossRef Riemann, D., Baglioni, C., & Bassetti, C. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675–700. PubMedCrossRef
go back to reference Roth, T., Arnold, L. M., Garcia-Borreguero, D., Resnick, M., & Clair, A. G. (2014). A review of the effects of pegabalin on sleep disturbance across multiple clinical conditions. Sleep Medicine Reviews, 18(3): 261–271. Roth, T., Arnold, L. M., Garcia-Borreguero, D., Resnick, M., & Clair, A. G. (2014). A review of the effects of pegabalin on sleep disturbance across multiple clinical conditions. Sleep Medicine Reviews, 18(3): 261–271.
go back to reference Rottach, K. G., Schaner, B. M., Kirch, M. H., Zivotofsky, A. Z., Teufel, L. M., & Gallwitz, T., et al. (2008). Restless legs syndrome as side effect of second generation antidepressants. Journal of Psychiatric Research, 43(1), 70–75. Rottach, K. G., Schaner, B. M., Kirch, M. H., Zivotofsky, A. Z., Teufel, L. M., & Gallwitz, T., et al. (2008). Restless legs syndrome as side effect of second generation antidepressants. Journal of Psychiatric Research, 43(1), 70–75.
go back to reference Rudisill, T. M., Zhu, M., Kelley, G. A., Pilkerton, C., & Rudisill, B. R. (2016). Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review. Accident Analysis and Prevention, 96, 255–270. PubMedPubMedCentralCrossRef Rudisill, T. M., Zhu, M., Kelley, G. A., Pilkerton, C., & Rudisill, B. R. (2016). Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review. Accident Analysis and Prevention, 96, 255–270. PubMedPubMedCentralCrossRef
go back to reference Russel, I. J., Crofford, L. J., Leon, T., et al. (2009). The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Medicine, 10(6), 604–610. CrossRef Russel, I. J., Crofford, L. J., Leon, T., et al. (2009). The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Medicine, 10(6), 604–610. CrossRef
go back to reference Salin-Pasqual, R. J., Herrera-Estrella, M., Galicia-Polo, L., et al. (1999). Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biological Psychiatry, 46(1), 141–143. CrossRef Salin-Pasqual, R. J., Herrera-Estrella, M., Galicia-Polo, L., et al. (1999). Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biological Psychiatry, 46(1), 141–143. CrossRef
go back to reference Salminen, A. V., & Winkelmann, J. (2018). Restless legs syndrome and other movement disorders of sleep-treatment update. Current Treatment Options in Neurology, 20(12), 55. PubMedCrossRef Salminen, A. V., & Winkelmann, J. (2018). Restless legs syndrome and other movement disorders of sleep-treatment update. Current Treatment Options in Neurology, 20(12), 55. PubMedCrossRef
go back to reference Salvi, V., Mencacci, C., & Barone-Adesi, F. (2016). H1-histamine receptor affinity predicts weight gain with antidepressants. European Neuropsychopharmacology, 26(10), 1673–1677. PubMedCrossRef Salvi, V., Mencacci, C., & Barone-Adesi, F. (2016). H1-histamine receptor affinity predicts weight gain with antidepressants. European Neuropsychopharmacology, 26(10), 1673–1677. PubMedCrossRef
go back to reference Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American academy of sleep medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(2), 307–349. PubMedPubMedCentralCrossRef Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American academy of sleep medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(2), 307–349. PubMedPubMedCentralCrossRef
go back to reference Schierenbeck, T., Riemann, D., Berger, M., & Hornyak, M. (2008). Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Medicine Reviews, 12(5), 381–389. Schierenbeck, T., Riemann, D., Berger, M., & Hornyak, M. (2008). Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Medicine Reviews, 12(5), 381–389.
go back to reference Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019). An insight into Z-drug abuse and dependence: An examination of reports to the European medicines agency database of suspected adverse drug reactions. International Journal of Neuropsychopharmacology, 22(4), 270–277. PubMedCentralCrossRefPubMed Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019). An insight into Z-drug abuse and dependence: An examination of reports to the European medicines agency database of suspected adverse drug reactions. International Journal of Neuropsychopharmacology, 22(4), 270–277. PubMedCentralCrossRefPubMed
go back to reference Schittecatte, M., Dumont, F., Machowski, R., et al. (2002). Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology, 46, 197–201. PubMedCrossRef Schittecatte, M., Dumont, F., Machowski, R., et al. (2002). Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology, 46, 197–201. PubMedCrossRef
go back to reference Schmid, D. A., Wichniak, A., Uhr, M., et al. (2006). Changes of sleep archictecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology, 31, 832–844. PubMedCrossRef Schmid, D. A., Wichniak, A., Uhr, M., et al. (2006). Changes of sleep archictecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology, 31, 832–844. PubMedCrossRef
go back to reference Schonmann, Y., Goren, O., Bareket, R., Comaneshter, D., Cohen, A. D., & Vinker, S. (2018). Chronic hypnotic use at 10 years-does the brand matter? European Journal of Clinical Pharmacology, 74(12), 1623–1631. PubMedCrossRef Schonmann, Y., Goren, O., Bareket, R., Comaneshter, D., Cohen, A. D., & Vinker, S. (2018). Chronic hypnotic use at 10 years-does the brand matter? European Journal of Clinical Pharmacology, 74(12), 1623–1631. PubMedCrossRef
go back to reference Schreiber, S., & Pick, C. G. (2020). Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep? Medical Hypotheses, 136, 190501. CrossRef Schreiber, S., & Pick, C. G. (2020). Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep? Medical Hypotheses, 136, 190501. CrossRef
go back to reference Schweitzer, P. K., & Feren, S. D. (2017). Pharmacological Treatment of Insomnia. In H. Attarian (red.), Clinical handbook of insomnia. Current clinical neurology. Springer: Cham. Schweitzer, P. K., & Feren, S. D. (2017). Pharmacological Treatment of Insomnia. In H. Attarian (red.), Clinical handbook of insomnia. Current clinical neurology. Springer: Cham.
go back to reference Seeman, D. (2014). Clozapine, a fast-off-D2 antipsychotic. ACS Chemical Neuroscience, 5(1), 24–29. PubMedCrossRef Seeman, D. (2014). Clozapine, a fast-off-D2 antipsychotic. ACS Chemical Neuroscience, 5(1), 24–29. PubMedCrossRef
go back to reference Shen, J., Chung, S. A., Kayumov, L., et al. (2006). Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Canadian Journal of Psychiatry, 51, 27–34. PubMedCrossRef Shen, J., Chung, S. A., Kayumov, L., et al. (2006). Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Canadian Journal of Psychiatry, 51, 27–34. PubMedCrossRef
go back to reference Shuman, M., Chukwu, A., Van Veldhuizen, N., & Miller, S. A. (2019). Relationship between mirtazapine dose and incidence of adrenergic side effects: An exploratory analysis. Mental Health Clinician, 9, 41–47. PubMedCrossRefPubMedCentral Shuman, M., Chukwu, A., Van Veldhuizen, N., & Miller, S. A. (2019). Relationship between mirtazapine dose and incidence of adrenergic side effects: An exploratory analysis. Mental Health Clinician, 9, 41–47. PubMedCrossRefPubMedCentral
go back to reference Sivertsen, B., Omvik, S., Pallesen, S., Nordhus, I. H., & Bjorvatn, B. (2009). Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs. Journal of Clinical Sleep Medicine, 5(4), 349–354. PubMedPubMedCentralCrossRef Sivertsen, B., Omvik, S., Pallesen, S., Nordhus, I. H., & Bjorvatn, B. (2009). Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs. Journal of Clinical Sleep Medicine, 5(4), 349–354. PubMedPubMedCentralCrossRef
go back to reference Smith, C., & Koola, M. M. (2016). Evidence for using doxazosin in the treatment of posttraumatic stress disorder. Psychiatric Annals, 46(9), 553–555. PubMedPubMedCentralCrossRef Smith, C., & Koola, M. M. (2016). Evidence for using doxazosin in the treatment of posttraumatic stress disorder. Psychiatric Annals, 46(9), 553–555. PubMedPubMedCentralCrossRef
go back to reference Stahl, S. (2009). Stahl’s essential psychopharmacology. The prescriber’s guide. Derde editie. Verenigd Koninkrijk: Cambridge University Press. Stahl, S. (2009). Stahl’s essential psychopharmacology. The prescriber’s guide. Derde editie. Verenigd Koninkrijk: Cambridge University Press.
go back to reference Stahl, S., & Morrissette, D. A. (2016). Stahl’s illustrated sleep and wake disorders. Verenigd Koninkrijk: Cambridge University Press. Stahl, S., & Morrissette, D. A. (2016). Stahl’s illustrated sleep and wake disorders. Verenigd Koninkrijk: Cambridge University Press.
go back to reference Stein, D. J., Ahokas, A. A., & De Bodinat, C. (2008). Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 28, 561–566. PubMedCrossRef Stein, D. J., Ahokas, A. A., & De Bodinat, C. (2008). Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 28, 561–566. PubMedCrossRef
go back to reference Storebø, O. J., Pedersen, N., Ramstad, E., et al. (2018). Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non-randomized studies. Cochrane Database of Systematic Reviews, 9(5), CD012069. Storebø, O. J., Pedersen, N., Ramstad, E., et al. (2018). Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non-randomized studies. Cochrane Database of Systematic Reviews, 9(5), CD012069.
go back to reference Sun, H., Kennedy, W. P., Wilbraham, D., Lewis, N., Calder, N., Li, X., et al. (2013). Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep, 36(2), 259–267. PubMedPubMedCentral Sun, H., Kennedy, W. P., Wilbraham, D., Lewis, N., Calder, N., Li, X., et al. (2013). Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep, 36(2), 259–267. PubMedPubMedCentral
go back to reference Takaesu, Y., Komada, Y., Asaoka, S., Kagimura, T., & Inoue, Y. (2014 Nov 19). Factors associated with long-term use of hypnotics among patients with chronic insomnia. PLoS One, 9(11), e113753. Takaesu, Y., Komada, Y., Asaoka, S., Kagimura, T., & Inoue, Y. (2014 Nov 19). Factors associated with long-term use of hypnotics among patients with chronic insomnia. PLoS One, 9(11), e113753.
go back to reference Takaesu, Y., Utsumi, T., Okajima, I., et al. (2019). Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: A systematic review and meta-analysis. Sleep Medicine Reviews, 48, 101214. PubMedCrossRef Takaesu, Y., Utsumi, T., Okajima, I., et al. (2019). Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: A systematic review and meta-analysis. Sleep Medicine Reviews, 48, 101214. PubMedCrossRef
go back to reference Tan, L., Zhou, J., Yang, L., Ren, R., Zhang, Y., Li, T., et al. (2017). Duloxetine-induced rapid eye movement sleep behavior disorder: A case report. BMC Psychiatry, 17(1), 372. PubMedPubMedCentralCrossRef Tan, L., Zhou, J., Yang, L., Ren, R., Zhang, Y., Li, T., et al. (2017). Duloxetine-induced rapid eye movement sleep behavior disorder: A case report. BMC Psychiatry, 17(1), 372. PubMedPubMedCentralCrossRef
go back to reference Taylor, F. B., Martin, P., Thomposon, C., et al. (2008). Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma PTSD: A placebo-controlled study. Biological Psychiatry, 63(6), 629–632. Taylor, F. B., Martin, P., Thomposon, C., et al. (2008). Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma PTSD: A placebo-controlled study. Biological Psychiatry, 63(6), 629–632.
go back to reference Taylor, H. L., Rybarczyk, B. D., Nay, W., & Leszczyszyn, D. (2015). Effectiveness of a CBT intervention for persistent insomnia and hypnotic dependency in an outpatient psychiatry clinic. Journal of Clinical Psychology, 71(7), 666–683. PubMedCrossRef Taylor, H. L., Rybarczyk, B. D., Nay, W., & Leszczyszyn, D. (2015). Effectiveness of a CBT intervention for persistent insomnia and hypnotic dependency in an outpatient psychiatry clinic. Journal of Clinical Psychology, 71(7), 666–683. PubMedCrossRef
go back to reference Thompson, W., Quay, T. A. W., Rojas-Fernandez, C., et al. (2016). Atypical antipsychotics for insomnia: A systematic review. Sleep Medicine, 22, 13–17. PubMedCrossRef Thompson, W., Quay, T. A. W., Rojas-Fernandez, C., et al. (2016). Atypical antipsychotics for insomnia: A systematic review. Sleep Medicine, 22, 13–17. PubMedCrossRef
go back to reference Thorpy, M. J., & Bogan, R. K. (2020). Update on the pharmacologic management of narcolepsy: Mechanisms of action and clinical implications. Sleep Medicine, 68, 97–109. PubMedCrossRef Thorpy, M. J., & Bogan, R. K. (2020). Update on the pharmacologic management of narcolepsy: Mechanisms of action and clinical implications. Sleep Medicine, 68, 97–109. PubMedCrossRef
go back to reference Trenkwalder, C., Allen, R., Högl, B., Clemens, S., Patton, S., Schormair, B., et al. (2018). Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurology, 17(11), 994–1005. PubMedCrossRef Trenkwalder, C., Allen, R., Högl, B., Clemens, S., Patton, S., Schormair, B., et al. (2018). Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurology, 17(11), 994–1005. PubMedCrossRef
go back to reference Tribl, G. G., Wetter, T. C., & Schredl, M. (2013). Dreaming under antidepressants: A systematic review on evidence in depressive patients and healthy volunteers. Sleep Medicine Reviews, 17(2), 133–142. PubMedCrossRef Tribl, G. G., Wetter, T. C., & Schredl, M. (2013). Dreaming under antidepressants: A systematic review on evidence in depressive patients and healthy volunteers. Sleep Medicine Reviews, 17(2), 133–142. PubMedCrossRef
go back to reference Uca, A. U., Uğuz, F., Kozak, H. H., et al. (2015). Antidepressant-induced sleep bruxism: Prevalence, incidence, and related factors. Clinical Neuropharmacology, 38, 227–230. Uca, A. U., Uğuz, F., Kozak, H. H., et al. (2015). Antidepressant-induced sleep bruxism: Prevalence, incidence, and related factors. Clinical Neuropharmacology, 38, 227–230.
go back to reference Uchiyama, M., Sakamoto, S., & Miyata, L. (2019). Effect of ramelteon on insomnia severity: Evaluation of patient characteristics affecting treatment response. Sleep and Biological Rhythms, 17, 379–388. CrossRef Uchiyama, M., Sakamoto, S., & Miyata, L. (2019). Effect of ramelteon on insomnia severity: Evaluation of patient characteristics affecting treatment response. Sleep and Biological Rhythms, 17, 379–388. CrossRef
go back to reference Vande Griend, J. P., Anderson, S. L. (2012). Histamine-1 receptor antagonism for treatment of insomnia. Journal of the American Pharmacists Association, 52(6), e210–e219. Vande Griend, J. P., Anderson, S. L. (2012). Histamine-1 receptor antagonism for treatment of insomnia. Journal of the American Pharmacists Association, 52(6), e210–e219.
go back to reference Vermeeren, A., Wolschrijn, H., Leufkens, T. R. M., Theunissen, E. L., Kuypers, K. P. C., & Ramaekers, J. G. (2010). Psychofarmaca en rijvaardigheid. Psyfar, 2, 62–65. Vermeeren, A., Wolschrijn, H., Leufkens, T. R. M., Theunissen, E. L., Kuypers, K. P. C., & Ramaekers, J. G. (2010). Psychofarmaca en rijvaardigheid. Psyfar, 2, 62–65.
go back to reference Vermetten, E. (2017). Stand van zaken van de farmacotherapie voor PTSS, deel I: Overzicht en update. Psyfar, 2, 18–26. Vermetten, E. (2017). Stand van zaken van de farmacotherapie voor PTSS, deel I: Overzicht en update. Psyfar, 2, 18–26.
go back to reference Vicens, C., Sempere, E., Bejarano, F., et al. (2016). Efficacy of two interventions on the discontinuation of benzodiazepines in long-term users: 36-month follow-up of a cluster randomised trial in primary care. British Journal of General Practice, 66(643), e85–e91. Vicens, C., Sempere, E., Bejarano, F., et al. (2016). Efficacy of two interventions on the discontinuation of benzodiazepines in long-term users: 36-month follow-up of a cluster randomised trial in primary care. British Journal of General Practice, 66(643), e85–e91.
go back to reference Vickers-Smith, R., Sun, J., Charnigo, R. J., Lofwall, M. R., Walsh, S. L., & Havens, J. R. (2020). Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system. Drug and Alcohol Dependence, 1(206), 107709. CrossRef Vickers-Smith, R., Sun, J., Charnigo, R. J., Lofwall, M. R., Walsh, S. L., & Havens, J. R. (2020). Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system. Drug and Alcohol Dependence, 1(206), 107709. CrossRef
go back to reference Wade, A. G., Ford, I., Crawford, G., et al. (2010). Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Medicine, 8, 51. PubMedPubMedCentralCrossRef Wade, A. G., Ford, I., Crawford, G., et al. (2010). Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Medicine, 8, 51. PubMedPubMedCentralCrossRef
go back to reference Walsh, J. K., Erman, M., Erwin, C. W., et al. (1998). Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Human Psychopharmacology, 13(3), 191–198. CrossRef Walsh, J. K., Erman, M., Erwin, C. W., et al. (1998). Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Human Psychopharmacology, 13(3), 191–198. CrossRef
go back to reference Weber, J., Siddiqui, M. A. A., Wagstaff, A. J., et al. (2010). Low-Dose Doxepin. CNS Drugs, 24, 713–720. PubMedCrossRef Weber, J., Siddiqui, M. A. A., Wagstaff, A. J., et al. (2010). Low-Dose Doxepin. CNS Drugs, 24, 713–720. PubMedCrossRef
go back to reference Williams, R. R., & Sandigo, G. (2017). Venlafaxine-induced REM sleep behavioral disorder presenting as two fractures. Trauma Case Reports, 11, 18–19. CrossRef Williams, R. R., & Sandigo, G. (2017). Venlafaxine-induced REM sleep behavioral disorder presenting as two fractures. Trauma Case Reports, 11, 18–19. CrossRef
go back to reference Wilson, S., & Argyropoulos, S. (2005). Antidepressants and Sleep. CNS Drugs, 65, 927–947. CrossRef Wilson, S., & Argyropoulos, S. (2005). Antidepressants and Sleep. CNS Drugs, 65, 927–947. CrossRef
go back to reference Wilson, S. J., Bailey, J. E., & Rich, A. S. (2005). The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. Journal of Psychopharmacology, 19, 609–613. PubMedCrossRef Wilson, S. J., Bailey, J. E., & Rich, A. S. (2005). The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. Journal of Psychopharmacology, 19, 609–613. PubMedCrossRef
go back to reference Wilson, S., Højer, A. M., Buchberg, J., Areberg, J., & Nutt, D. J. (2015). Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. Journal of Psychopharmacology, 29(10), 1085–1091. PubMedCrossRef Wilson, S., Højer, A. M., Buchberg, J., Areberg, J., & Nutt, D. J. (2015). Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. Journal of Psychopharmacology, 29(10), 1085–1091. PubMedCrossRef
go back to reference Winokur, A., Gary, K. A., Rodner, S., Rae-Red, C., Fernando, A. T., & Szuba, M. P. (2001). Depression, sleep physiology, and antidepressant drugs. Depression and Anxiety, 14, 19–28. PubMedCrossRef Winokur, A., Gary, K. A., Rodner, S., Rae-Red, C., Fernando, A. T., & Szuba, M. P. (2001). Depression, sleep physiology, and antidepressant drugs. Depression and Anxiety, 14, 19–28. PubMedCrossRef
go back to reference Wong, C. K., Marshall, N. S., Grunstein, R. R., Ho, S. S., Fois, R. A., Hibbs, D. E., et al. (2017 Feb 15). Spontaneous adverse event reports associated with zolpidem in the United States 2003–2012. Journal of Clinical Sleep Medicine, 13(2), 223–234. Wong, C. K., Marshall, N. S., Grunstein, R. R., Ho, S. S., Fois, R. A., Hibbs, D. E., et al. (2017 Feb 15). Spontaneous adverse event reports associated with zolpidem in the United States 2003–2012. Journal of Clinical Sleep Medicine, 13(2), 223–234.
go back to reference Wright, A., Diebold, J., Otal, J., Stoneman, C., Wong, J., Wallace, C., et al. (2015). The effect of melatonin on benzodiazepine discontinuation and sleep quality in adults attempting to discontinue benzodiazepines: A systematic review and meta-analysis. Drugs and Aging, 32(12), 1009–1018. PubMedCrossRef Wright, A., Diebold, J., Otal, J., Stoneman, C., Wong, J., Wallace, C., et al. (2015). The effect of melatonin on benzodiazepine discontinuation and sleep quality in adults attempting to discontinue benzodiazepines: A systematic review and meta-analysis. Drugs and Aging, 32(12), 1009–1018. PubMedCrossRef
go back to reference Wynchank, D., Bijlenga, D., Beekman, A. T., Kooij, J. J. S., Penninx, B. W. (2017 Oct 30). Adult attention-deficit/hyperactivity disorder (ADHD) and insomnia: An update of the literature. Current Psychiatry Reports, 19(12), 98. Wynchank, D., Bijlenga, D., Beekman, A. T., Kooij, J. J. S., Penninx, B. W. (2017 Oct 30). Adult attention-deficit/hyperactivity disorder (ADHD) and insomnia: An update of the literature. Current Psychiatry Reports, 19(12), 98.
go back to reference Yamada, Y., Shibuya, F., Hamada, J., Sawada, Y., & Iga, T. (1995). Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy. Journal of Pharmacokinetics and Biopharmaceutics, 23(2), 131–145. PubMedCrossRef Yamada, Y., Shibuya, F., Hamada, J., Sawada, Y., & Iga, T. (1995). Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy. Journal of Pharmacokinetics and Biopharmaceutics, 23(2), 131–145. PubMedCrossRef
go back to reference Yeh, M. S., Mari, J. J., Costa, M. C., Andreoli, S. B., Bressan, R. A., & Mello, M. F. (2011). A Double-Blind Randomized Controlled Trial To Study the Efficacy of Topiramate in a Civilian Sample of PTSD. CNS Neuroscience & Therapeutics, 17(5), 305–310. CrossRef Yeh, M. S., Mari, J. J., Costa, M. C., Andreoli, S. B., Bressan, R. A., & Mello, M. F. (2011). A Double-Blind Randomized Controlled Trial To Study the Efficacy of Topiramate in a Civilian Sample of PTSD. CNS Neuroscience & Therapeutics, 17(5), 305–310. CrossRef
go back to reference Zapp, A. A., Fischer, E., & Deuschle, M. (2017). The effect of agomelatine and melatonin on sleep-related eating: A case report. Journal of Medical Case Reports, 11, 275. PubMedPubMedCentralCrossRef Zapp, A. A., Fischer, E., & Deuschle, M. (2017). The effect of agomelatine and melatonin on sleep-related eating: A case report. Journal of Medical Case Reports, 11, 275. PubMedPubMedCentralCrossRef
Metagegevens
Titel
Psychofarmaca en de behandeling van slaapstoornissen
Auteurs
drs. Maaike van Veen
dr. Jeanine Kamphuis
dr. Rixt Riemersma-van der Lek
Copyright
2021
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-2524-5_19